Tomography News and Research

RSS

Common household chemicals may slow bone development in boys

Gestational exposure to chemicals in plastics and furniture may relate to slower bone mineral accrual in adolescence, particularly among males.

12 Nov 2026

Type 2 diabetes accelerates jawbone loss and causes tooth loss

Type 2 diabetes (T2D) is a chronic metabolic disorder whose global burden continues to rise. Beyond its systemic effects, T2D compromises skeletal health and markedly worsens loss of alveolar bone—the bone that anchors teeth—leading to tooth loosening, increased mobility, and eventual tooth loss.

11 Nov 2026

Artery scans detect “silent atherosclerosis” in 1 in 13 adults under 30

Researchers studying 16,808 adults aged 18 to 70 found that silent atherosclerosis was detectable in early adulthood, with plaque present in 57.1% of those who completed imaging across three arterial territories. Plaque prevalence and burden were higher in older age groups, with men showing earlier evidence of disease than women, while conventional cardiovascular risk scores identified relatively few people with existing plaque.

10 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

10 Nov 2026

Qureight's fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight's Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum's PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum's lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

From Qureight 9 Nov 2026

First Medicare ExRad study reveals wide variation in CT radiation

The first study to examine how imaging facilities perform on the new Medicare "ExRad" measure shows that radiation doses used for the same type of CT scan vary widely from one facility to the next.

3 Nov 2026

New pediatric consensus standardizes surgical management of Wilms tumor

WT outcomes have improved substantially through progress in molecular diagnosis, chemotherapy, radiotherapy, and surgery. Yet surgical management remains inconsistent, especially for large tumors, adjacent-organ invasion, intravascular extension, nephron-sparing surgery (NSS), and lymph node biopsy.

2 Nov 2026

Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced the publication of a peer-reviewed Viewpoint in the European Respiratory Journal (ERJ).

From Qureight 2 Nov 2026

Randomized trial demonstrates enhanced stent expansion in severely calcified coronary nodules

A randomized clinical trial at The Mount Sinai Hospital found that combining two techniques for removing calcium nodules-rotational atherectomy and intravascular lithotripsy (IVL)-before coronary stent placement allowed stents to expand more fully than IVL alone in patients with calcified coronary nodules.

2 Nov 2026

Researchers uncover molecular pathway controlling bone resorption and tooth eruption

RUNX2 is best known as a master transcription factor of osteoblast differentiation. Mutations in, or haploinsufficiency of RUNX2 cause CCD, a skeletal disorder characterized by delayed permanent tooth eruption, supernumerary teeth and clavicular defects.

30 Oct 2026

Label-free microscopy technique films cell activity in 3D

Researchers at the University of Tokyo have developed a high-speed microscopy technique which captures images so quickly they can be used to make "videos" of the dynamic processes which occur inside living cells.

30 Oct 2026

New research center aims to accelerate hepatitis C vaccine development

The shifty hepatitis C virus (HCV) has a knack for outmaneuvering the immune system. Its secret is an especially high mutation rate, which has generated an abundance of viral variants with extreme genetic diversity.

27 Oct 2026

CT scans linked vitamin D levels to fat within muscles after bariatric surgery

Researchers followed 113 adults for one year after bariatric surgery and found that those with higher postoperative vitamin D concentrations had less fat infiltration within certain muscles and lower visceral adiposity. They found no significant association between increases in vitamin D and changes in body composition after correction for multiple comparisons, while preoperative vitamin D levels did not independently predict postoperative body composition.

27 Oct 2026

Amyloid fibers help sperm deliver RNA to mouse embryos

Researchers identified RNA-associated amyloid fibrils in human seminal fluid and demonstrated that synthetic PAP fibrils could enter mammalian sperm. In mouse IVF experiments, these fibrils helped sperm deliver RNA to embryos, where the detected reporter-protein signal was at least tenfold higher than without fibril exposure.

27 Oct 2026

Proteins linked to Alzheimer's found to assist sperm cells

Unexpectedly, a kind of protein that is usually linked with diseases in the brain may play a vital role in semen, helping shepherd genetic material into sperm cells, scientists at Columbia's Zuckerman Institute report today in the research journal Molecular Cell.

26 Oct 2026

Newly discovered protein controls the space between mitochondrial membranes

Mitochondria are the tiny powerpacks that supply most of the energy our cells need. Their ability to generate this energy relies on a distinctive architecture: two membranes, one tucked inside the other, separated by a narrow gap called the intermembrane space (IMS).

23 Oct 2026

What can 6,000 brain scans tell us about Alzheimer's?

KARI's multimodal imaging dataset reveals critical insights into Alzheimer's disease, linking amyloid, tau, and brain structure to cognitive performance.

23 Oct 2026

Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands

Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced it has been selected by Celea Therapeutics as the imaging CRO to support Celea’s Phase 3 SURPASS-IPF clinical trial.

From Qureight 21 Oct 2026

New study could help reduce radiation exposure during cardiac CT scans

A new study at The University of Texas at Arlington could help substantially reduce the amount of radiation heart patients receive during imaging procedures without sacrificing diagnostic accuracy.

15 Oct 2026

AI study of 101,000 patients links brown fat to heart and mental health

In a retrospective analysis of PET-CT records from 101,243 patients, researchers found that detectable brown fat was associated with lower prevalence of cardiometabolic and psychiatric conditions, while greater activity, particularly in the axillary region, was linked to more favourable metabolic outcomes. Medication screening identified losartan, which increased brown fat thermogenic activity in laboratory experiments and energy expenditure in mice, although its effects on human brown fat remain unproven.

15 Oct 2026